80860-34-0

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 3847-27-6 Kanamycin A sulfate 
• 1538-75-6 2,2-dimethylpropanoic anhydride 
• 59-01-8 kanamycin A 
• 74256-73-8 3,6'-bis(N-benzyloxycarbonyl)-3-N-(trifluoroacetyl)kanamycin A 
• 41840-28-2 S-tert-butoxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine 

Downstream Products

• 80860-35-1 4'',6''-O-cyclohexylidene-tetra-N-tert-butoxycarbonylkanamycin A 
• 953395-49-8 6''-(2,4,6-triisopropylbenzenesulfonyl)-1,3,6',3''-tetra-N-(tert-butoxycarbonyl)kanamycin A 
• 1203670-04-5 C₈₇H₁₀₃N₁₁O₂₆ 
• 953395-50-1 1,3,6',3''-tetra-N-(tert-butoxycarbonyl)-6''-azido-6''-deoxy-kanamycin A 
• 1203669-89-9 1,3,6',3''-tetra-N-(tert-butoxycarbonyl)-6''-amino-6''-deoxy-kanamycin A 

Relevant academic research and scientific papers

Amphiphilic aminoglycosides with increased selectivity for inhibition of connexin 43 (Cx43) hemichannels

Gap junction channels formed by the association of connexin hemichannels play a crucial role in intercellular communication. Connexin 43 (Cx43) is expressed in a variety of tissues and organs, including heart and brain, and abnormal sustained opening of undocked “free” hemichannels contributes to the cell damage in cardiac infarcts and stroke. Selective inhibitors of Cx43 hemichannels for clinical use are then desirable. Here, we synthesized and tested new aminoglycosides for their connexin inhibitory activity towards Cx26 and Cx43 hemichannels. The lead compounds displayed enhanced Cx43/Cx26 selectivity for hemichannel inhibition when compared to the parent kanamycin A and other commercially available aminoglycosides. These lead compounds are not cytotoxic to mammalian cells and show promise for the treatment of ischemic damage of the heart, brain, and kidneys. We identified a new compound as a promising lead based on its good selectivity for Cx43 hemichannels inhibition and the simplicity and affordability of its production.

Rapid solid-phase syntheses of a peptidic-aminoglycoside library

A library of mono- and di-amino acid peptidic-aminoglycosides (PAs), with kanamycin and neomycin as the model aminoglycosides, was systematically and rapidly synthesized via solid phase peptide synthesis. Aminoglycosides were first converted into N-Boc pr

COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION

The present invention provides compounds, compositions thereof, and methods of using the same.

COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES

The present invention provides compounds, compositions thereof, and methods of using the same.

Regulating miRNA-21 Biogenesis by Bifunctional Small Molecules

We report a new strategy to regulate microRNAs (miRNAs) biogenesis by using bifunctional small molecules that consist of a pre-miRNA binding unit connected by a linker to a Dicer inhibiting unit. In this effort, fluorescence polarization-based screening was used to identify neomycin as a pre-miR-21 binding ligand. Although neomycin cannot inhibit miR-21 maturation, linking it to the RNase inhibitor 1 forms the bifunctional conjugate 7A, which inhibits the production of miR-21. We expect that this strategy will be applicable to design other molecules for miRNA regulation.

Synthesis of new biocarrier-nucleotide systems for cellular delivery in bacterial auxotrophic strains

In search for a delivery approach for thymidine monophosphate (TMP) in bacterial cells, we have synthesized a series of conjugates of TMP with biotin having an oxymethyleneoxy ester, a carboxy ester, and different carboxamide linkers between the carboxyl group of biotin and the 3′-OH group of TMP. The synthetic strategy starts from 5′-O-(dibenzylphosphate)-thymidine having the linkers already connected at the 3′-position. Likewise, kanamycin A was linked at the 3′-position of TMP using a carbamoyl or thioethyl carbamoyl group. None of the conjugates were able to sustain growth of a ΔthyA, ΔphoA Escherichia coli strain.

Enhanced RNA binding of dimerized aminoglycosides

Aminoglycoside antibiotics have recently emerged as an intriguing family of RNA binding molecules and they became leading structures for the design of novel RNA ligands. The demystification of the aminoglycoside-RNA recognition phenomenon is required for